

PRESS RELEASE

Bresso, Milan, February 26, 2025

Massimo Grandi joins Zambon as Chief Core Therapies Officer

In his new role, Grandi will be responsible for further developing Zambon's core products, expanding into new markets, new channels, and new opportunities.

Zambon, a multinational chemical-pharmaceutical company founded on the history and values of a family business committed to improving patients' lives and health, announces **the appointment of Massimo Grandi as Chief Core Therapies Officer**. His objective will be to further strengthen the positioning of Zambon's core products, as well as opening up new markets, new channels, and new opportunities.

Grandi's arrival confirms Zambon's strategic direction, which stands in continuity with its history and the aim of shaping the future through innovation in patient care and is strengthening its two strategic business units: **the Core Therapies division**, led by Massimo Grandi, and **the Innovative Therapies division**, which will be headed by Mirko Merletti as Chief Innovative Therapies Officer. Merletti is an experienced international pharmaceutical industry executive who previously served as Zambon's Chief Commercial Officer.

"We are focused on growing our assets and launching new projects, strengthening our operational model and expanding our presence in the many markets where Zambon operates," said Giovanni Magnaghi, CEO of Zambon. "We are convinced that Core Therapies have significant growth potential, and that Innovative Therapies will enhance our portfolio, enabling us to continue growing with our usual determination. To achieve this, we need cross-functional expertise and experience like the one brought by Massimo Grandi. We will continue to invest in our products to fully unlock their potential, staying true to our commitment to Innovate cure & care to make patients' lives better."

"I am very happy to have joined a company with such a long history and a unique industrial heritage. Zambon has strong brand equity and a solid, well-established product portfolio across global markets, reflecting a company with deep-rooted values and a clear vision for the future," commented Massimo Grandi.

Grandi joins Zambon from Recordati. He holds a degree in Pharmaceutical Chemistry and Technology from the University of Pisa and earned an Executive MBA from SDA Bocconi in Milan. Along his career, he has contributed to the strong growth of pharmaceutical companies both in Italy and internationally, leading the launch of market-leading brands in the OTC and Specialty segments. In addition to Recordati, his international experience includes roles at Servier, Angelini, and Daiichi Sankyo.

##

Zambon SpA

Zambon SpA is a multinational pharmaceutical company established in 1906 in Vicenza, whose history is founded on the values of an Italian family committed to innovating cure & care to improve patients' lives. It employs more than 2,500 people worldwide, it is present in 23 countries in Europe, America and Asia, and has production facilities in Italy, Switzerland, China and Brazil. Thanks to its innovative, quality products commercialized in 87 countries, Zambon SpA reported a revenue of 843 million euros in 2023. Alongside the three historical therapeutic areas - diseases of the respiratory system, urinary tract infections and pain treatment – Zambon is focused on developing treatments for neurodegenerative diseases such as Parkinson's or rare diseases such as cystic fibrosis, BOS (Bronchiolitis Obliterans Syndrome) to which is linked the major 2019 acquisition of Breath Therapeutics, and NCFB (Non-cystic Fibrosis Bronchiectasis).

For further information on Zambon please visit www.zambon.com

Media Contacts

media@zambongroup.com